Immuron(US:IMRN) Newsfilter·2024-05-31 10:00Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [2][3] - The company is listed on both the Australian Securities Exchange (ASX: IMC) and NASDAQ (NASDAQ: IMRN) [2] Product Information - Travelan® is an orally administered passive immunotherapy designed to reduce the likelihood of contracting travelers' diarrhea, which is caused by pathogenic bacteria [3] - Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies that bind to diarrhea-causing bacteria, preventing colonization [3][8] - In Australia, Travelan® is registered as a medicine, while in Canada it is a licensed natural health product, and in the U.S., it is sold as a dietary supplement [3] Technology Platform - Immuron's proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum, allowing for the production of highly specific immunoglobulins to any enteric pathogen [5] - The platform technology enables the development of medicines across a wide range of infectious diseases by blocking viruses or bacteria at mucosal surfaces [5] Research and Development - IMM-124E, developed using Immuron's platform technology, is produced from the colostrum of immunized cattle and contains significant levels of polyclonal antibodies specific for enterotoxigenic E. coli (ETEC) [6][7] - The antibodies in IMM-124E exhibit stronger binding and neutralizing activity against various LPS antigens compared to those from unvaccinated cattle [8]